Current Clinical Trials in Pemphigus and Pemphigoid

Conclusions The clinical trials discussed here, which include several trials investigating novel therapeutic targets, demonstrate that translational research in pemphigus and pemphigoid is a fast-growing field. We thus expect that several novel treatments will be shortly available for the treatment of pemphigus and pemphigoid patients. Given the high, and thus far unmet, medical need in this field (110), this is highly encouraging and will hopefully improve the quality of life of the affected patients. In addition to the compounds and targets described here, several new targets have been recently identified in preclinical model systems, such as PDE4 or PI3Kδ inhibitors (111, 112). Hence, the preclinical pipeline is well developed and will contribute to the growing number of clinical trials in pemphigus and pemphigoid. Author Contributions KI and RL wrote the manuscript. KB prepared the figure. All authors read, commented on, and approved the final version of the manuscript. Funding This work was supported by research grants from the Deutsche Forschungsgemeinschaft: Clinical Research Unit Pemphigoid Diseases (KFO 303), the Excellence Cluster Precision Medicine in Chronic Inflammation (EXC 2167-390884018) and the Uehara Memorial Foundation. Conflict of Interest Statement During the last 3 years, RL has received research funding from Almirall, True North Therapeutics, UCB Pharma, ArgenX, TxCell, Topadur, Incyte and Admirx and fees for consulting or speaking from A...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research